Editor’s Letter

dorseyWelcome to the twelfth edition of HD Insights, released at the 2015 Huntington Study Group Annual Meeting and Ninth Annual HD Clinical Research Symposium. We are pleased to continue our mission to promote, disseminate, and facilitate research in HD. We thank our subscribers, our Editorial Board, our newest sponsors, Teva Pharmaceuticals and Raptor Pharmaceuticals, and our founding and longtime supporter, Lundbeck Inc., for their generous support of the periodical.

This edition highlights exciting current research and up-and-coming HD researchers. In our new “Meet the Next Generation” feature, we profile early- to mid-career investigators who have been recognized by the Huntington’s Disease Society of America and the HSG as investigators with promising futures in HD research. All six have been invited to attend the 2015 HSG Annual Meeting to present their work. With the second year of the Insights of the Year competition, we bring you nine of the most influential publications in HD from July 2014 to July 2015, identified by the winners of last year’s competition. Authors of the four most influential papers, selected by our Editorial Board and other researchers, will present their work in a special panel session at the HSG meeting. Dr. Maurice Zauderer, founder, president, and CEO of Vaccinex Inc., discusses his company and their monoclonal antibody VX15/2503, which has just entered Phase II trials in HD. For those who were unable to attend the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, CA this year, we summarize the HD-related highlights of that meeting. Finally, we continue to provide an up-to-date status report on HD clinical trials.

HD Insights strives to provide relevant, interesting, and useful information to the global HD research community in academia and industry. We will continue to introduce new features and new explorations in the coming year, and welcome your suggestions and submissions. If you would like to become a supporter, or submit an article, comment, or suggestion, please send us an email at editor@hdinsights.org. For a free electronic subscription, please send an email to subscribe@hdinsights.org. Thank you for your continued support.
– – RAY DORSEY, EDITOR I N CHIEF

Editorial Board Members
Ray Dorsey, MD — Editor, University of Rochester
Donald Kennedy, PhD — Stanford University
Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute
Rodrigo Osorio — Agrupación Chilena de Huntington
Bernard Ravina, MD — Voyager Therapeutics
Ralf Reilmann, MD, PhD — George Huntington Institute
Sarah Tabrizi, MBChB, PhD — University College London
Leslie Thompson, PhD — University of California Irvine

Contributors
Meredith A. Achey, BM
Chen Chang, PhD
Yijuang Chern, PhD
Janelle Drouin-Ouellet, PhD
Marta Fernández-Nogales, PhD
Chien-Hsiang Huang, PhD
Joshua L. Plotkin, PhD
Steven G. Potkin, MD
Amber L. Southwell, PhD
Zhiqun Tan, PhD
Romina Vuono, PhD
Edward J. Wild, PhD
X. William Yang, PhD

Publication Staff
Meredith A. Achey — Deputy Editor
Robin Taylor — Production Editor
Martin Holmes — Technical Editor
David Kolko — Distribution Specialist

Huntington Study Group
Shari Kinel, JD — HSG Executive Director
Liz McCarthy, BA — HSG Director, Special Programs
Heather Hare, BA — HSG Director, Communications & Outreach
Stevan Ramirez, MBA — HSG Director, Finance & Operations
Kristin Strazdins — HSG Accounting and Office Manager

HD INSIGHTS (TM)
DISCLOSURES: DR . DORSEY RECEIVES GRANT SUPPORT FROM PRANA BIOTECHNOLOGY, TEVA, AND THE HUNTINGTON STUDY GROUP.